#Johnson And Johnson Transdermal Drug Delivery Market

[unwelcome-ozian]

What information do you have about Johnson & Johnson?

Alza filed an NDA for the transdermal opioid analgesic product in December 1987 for post-operative use and for the relief of chronic cancer pain. Developed by J&J subsidiary Janssen Pharmaceutica, fentanyl has been marketed since 1968 under the Sublimaze brand. The drug is currently approved for I.V. administration and used primarily as a short-acting analgesic during anaesthesia. "This new drug delivery system will make it possible for the first time to use fentanyl . . . outside the operating room to control moderate to severe pain." Source

US opioids: Johnson and Johnson and drug distributors offer $26bn to end thousands of lawsuits. Source

The drug company Johnson & Johnson (J&J) has expressed regret after court documents unsealed in talcum powder litigation showed that it funded a 1971 study in which Pennsylvania prison inmates, most of them black, were injected subcutaneously with asbestos. Source

Asbestos Prisoner Study May Spell More Problems for Johnson & Johnson

WASHINGTON - Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.  The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 billion. Source

Johnson & Johnson paused all clinical trials of its experimental COVID-19 vaccine after a study participant became sick with an "unexplained illness."

Johnson & Johnson has suspended international trials of a drug in the same class as an experimental drug made by Portuguese pharmaceutical company Bial, whose tests in France left one person brain dead and five others hospitalised. Source

1982 - McNeil

Product Recalled - Tylenol (acetaminophen) capsules

Reason for Recall - Medicine laced with potassium cyanide (poison) resulting in several patient deaths.

2009 to 2011 - McNeil

Product Recalled - Several OTC medicines including Tylenol, Motrin, Benadryl, St. Joseph aspirin, Sudafed, Pepcid, Mylanta, Rolaids, Zyrtec, Zyrtec Eye Drops (tens of millions of bottles)

Reason for Recall - Unpleasant smells causing nausea; tiny metal shards in liquid medicines; wrong ingredient levels

2010 - DePuy [Pinnacle Systems]

Product Recalled - ASR Hip Resurfacing System and ASR XL Acetabular System (metal-on-metal hip implants)

Reason for Recall - Metal poisoning (metallosis); loosening of the implant or joint dislocation; additional surgeries

2012 - Ethicon

Product Recalled - Gynecare Prolift Kit, Gynecare Prolift+M Kit, Gynecare TVT Secure and Gynecare Prosima Pelvic Floor Repair System Kit (transvaginal mesh implants)

Reason for Recall - Perforation of organs; vaginal bleeding and scarring; mesh erosion; severe pain

2014 - Ethicon

Product Recalled - Power Morcellators

Reason for Recall - Spread of uterine cancer; rapid progression of the disease; death

2019 – Johnson & Johnson

Product Recalled – 33,000 bottles of Johnson’s Baby Powder

Reason for Recall – The FDA found a small amount of asbestos — a known carcinogen — in a sample

Xarelto

Number of Lawsuits - 13,511

Injuries - severe, sometimes deadly bleeding events, blood clots, wound leaks, infection

J&J was involved in seven of 2017’s top ten health-care-related verdicts.

The company was also involved in the third-largest pharmaceutical settlement with the U.S. Department of Justice. In 2013, J&J paid the Justice Department more than $2.2 billion. The settlement resolved civil and criminal allegations involving Risperdal, Invega and Natrecor.

May 2017

J&J paid $33 million to most U.S. states and the District of Columbia. The states charged J&J with misrepresenting the manufacturing practices behind certain drugs. This included its Motrin products. These products were later recalled.

Oz

[sqinsights]

Needle-Free Drug Delivery Devices: Painless Innovations Shaping Healthcare's Future

The Rise of Needle-Free Marvels: 

So, you’re tired of needles poking around, huh? Join the club! The global needle-free drug delivery devices market, valued at a cool USD 13.99 Billion in 2022, is here to change the game. And guess what? It’s projected to grow at a CAGR of 6.8% until 2031. Jet injectors and transdermal patches are the cool kids on the block, ditching needles like yesterday’s news.

Technology Triumphs: 

Jet injectors, the superheroes of the needle-free saga, use high-pressure streams of liquid to deliver drugs without the dreaded needle. Perfect for insulin and vaccine administration, they’re like the James Bond of drug delivery — precise and efficient. Meanwhile, transdermal patches are strutting their stuff with extended drug release abilities, tackling everything from smoking discontinuation to hormone therapy. Move over, needles; there’s a new gang in town.

End-User Drama: 

Healthcare facilities have long been the divas of the needle-free runway, emphasizing patient comfort and compliance. But hold the phone! Home healthcare settings are swooping in for the spotlight, especially after gaining traction during the COVID-19 pandemic. Who says you can’t administer your meds in the comfort of your own home?

Global Domination: 

North America, with its penchant for innovation and a well-oiled healthcare infrastructure, sits on the throne of the needle-free kingdom. However, the Asia-Pacific region is like the rising star — thanks to growing awareness, increased healthcare expenditure, and a higher number of seasoned individuals in the population. India and China are the MVPs here.

Driving Forces and Roadblocks:

Advancements in technology are like the fairy godmothers, transforming needle-free devices into precise and efficient wizards. Patients are ditching traditional injections for pain-free alternatives, improving compliance and outcomes. But, ahoy! Regulatory challenges and cost issues are the evil villains, trying to rain on the pain-free parade. It’s a battle, but the needle-free crusade marches on.

Competitive Circus: 

Enter the competitive landscape, where industry giants like 3M, Pfizer, and Johnson & Johnson are flexing their muscles. Newcomers like Zogenix and Portal Instruments are crashing the party with innovative technologies. PharmaJet, the biotech sensation, got a makeover with a purchase by Penjet Corporation. Antares Pharma is playing the microneedle game after acquiring Apostrophe. It’s a circus out there, folks!

For More Information: https://www.skyquestt.com/report/needle-free-drug-delivery-devices-market

Key Market Trends — 

A Rollercoaster of Innovation: Needle-free devices are not just for insulin and vaccines; they’re branching out into specialized therapeutics and biologics. Consumers are demanding painless drug delivery, especially those battling chronic illnesses. The industry is buzzing with technological advancements, ensuring better precision and usability. It’s not just a market; it’s a rollercoaster of pain-free possibilities.

Conclusion: 

In a world where needles are no longer the untouchable royals of drug delivery, needle-free innovations are stealing the show. The market’s journey from USD 13.99 Billion in 2022 to a whopping USD 25.29 Billion by 2031 is nothing short of a blockbuster. So, here’s to a future where injections are painless, drug delivery is precise, and healthcare is, well, a little less pokey. Cheers to the needle-free revolution!

About Us-

SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.

Contact Us-

SkyQuest Technology Consulting Pvt. Ltd.

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 617–230–0741

Email- info@skyquestt.com

Website: https://www.skyquestt.com

[market-spy]

Needle-Free Drug Delivery Devices: Painless Innovations Shaping Healthcare's Future

Welcome to the revolution in healthcare — where needles are getting the boot, and innovative drug delivery devices are taking center stage. In a world where traditional injections have often been synonymous with pain and discomfort, the global market for Needle-Free Drug Delivery Devices is making waves. But let’s ditch the robotic jargon and delve into the realm of painless injections with a touch of humor and a sprinkle of sarcasm.

The Rise of Needle-Free Marvels: 

So, you’re tired of needles poking around, huh? Join the club! The global needle-free drug delivery devices market, valued at a cool USD 13.99 Billion in 2022, is here to change the game. And guess what? It’s projected to grow at a CAGR of 6.8% until 2031. Jet injectors and transdermal patches are the cool kids on the block, ditching needles like yesterday’s news.

Technology Triumphs: 

Jet injectors, the superheroes of the needle-free saga, use high-pressure streams of liquid to deliver drugs without the dreaded needle. Perfect for insulin and vaccine administration, they’re like the James Bond of drug delivery — precise and efficient. Meanwhile, transdermal patches are strutting their stuff with extended drug release abilities, tackling everything from smoking discontinuation to hormone therapy. Move over, needles; there’s a new gang in town.

End-User Drama: 

Healthcare facilities have long been the divas of the needle-free runway, emphasizing patient comfort and compliance. But hold the phone! Home healthcare settings are swooping in for the spotlight, especially after gaining traction during the COVID-19 pandemic. Who says you can’t administer your meds in the comfort of your own home?

Global Domination: 

North America, with its penchant for innovation and a well-oiled healthcare infrastructure, sits on the throne of the needle-free kingdom. However, the Asia-Pacific region is like the rising star — thanks to growing awareness, increased healthcare expenditure, and a higher number of seasoned individuals in the population. India and China are the MVPs here.

Driving Forces and Roadblocks:

Advancements in technology are like the fairy godmothers, transforming needle-free devices into precise and efficient wizards. Patients are ditching traditional injections for pain-free alternatives, improving compliance and outcomes. But, ahoy! Regulatory challenges and cost issues are the evil villains, trying to rain on the pain-free parade. It’s a battle, but the needle-free crusade marches on.

Competitive Circus: 

Enter the competitive landscape, where industry giants like 3M, Pfizer, and Johnson & Johnson are flexing their muscles. Newcomers like Zogenix and Portal Instruments are crashing the party with innovative technologies. PharmaJet, the biotech sensation, got a makeover with a purchase by Penjet Corporation. Antares Pharma is playing the microneedle game after acquiring Apostrophe. It’s a circus out there, folks!

For More Information: https://www.skyquestt.com/report/needle-free-drug-delivery-devices-market

Key Market Trends — 

A Rollercoaster of Innovation: Needle-free devices are not just for insulin and vaccines; they’re branching out into specialized therapeutics and biologics. Consumers are demanding painless drug delivery, especially those battling chronic illnesses. The industry is buzzing with technological advancements, ensuring better precision and usability. It’s not just a market; it’s a rollercoaster of pain-free possibilities.

Conclusion: 

In a world where needles are no longer the untouchable royals of drug delivery, needle-free innovations are stealing the show. The market’s journey from USD 13.99 Billion in 2022 to a whopping USD 25.29 Billion by 2031 is nothing short of a blockbuster. So, here’s to a future where injections are painless, drug delivery is precise, and healthcare is, well, a little less pokey. Cheers to the needle-free revolution!

About Us-

SkyQuest Technology Group is a Global Market Intelligence, Innovation Management & Commercialization organization that connects innovation to new markets, networks & collaborators for achieving Sustainable Development Goals.

Contact Us-

SkyQuest Technology Consulting Pvt. Ltd.

1 Apache Way,

Westford,

Massachusetts 01886

USA (+1) 617–230–0741

Email- info@skyquestt.com

Website: https://www.skyquestt.com

[datahorizzon-research1]

The pain management market is expected to reach a market size of USD 102.5 Billion by 2032

The pain management market was valued at USD 75.2 billion in 2023 and is anticipated to reach USD 102.5 billion by 2032, with a compound annual growth rate (CAGR) of 3.5%.

Globally, the pain management market is experiencing significant growth, driven by several key factors. Firstly, an aging population contributes to the rising prevalence of chronic pain conditions, necessitating effective pain management solutions. Additionally, advancements in pain management technologies are playing a crucial role in driving market growth, offering patients a broader range of treatment options.

For Further Information Regarding this Report: Request a Free Sample

Pharmaceuticals constitute a major segment within the pain management market, with a wide range of medications available to alleviate pain, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant medications. However, concerns regarding the addictive nature and side effects of opioids have led to a shift towards non-pharmacological interventions such as physical therapy, acupuncture, and cognitive-behavioral therapy.

Additionally, advancements in drug delivery systems, such as transdermal patches and implantable devices, offer novel approaches to pain management, providing targeted and sustained relief while minimizing systemic side effects. The medical device segment of the pain management market is also experiencing significant growth, driven by technological innovations aimed at providing non-invasive and minimally invasive alternatives to traditional surgical procedures.

Neuromodulation devices, such as spinal cord stimulators and peripheral nerve stimulators, have gained traction as effective therapies for chronic pain conditions, offering patients a means to manage their pain without relying solely on medication. Furthermore, the integration of artificial intelligence and digital health technologies into pain management devices has the potential to revolutionize patient care by enabling personalized treatment regimens and remote monitoring.

Want to change the report scope? Ask for Customization?

Top Companies are:

Pfizer Inc.

Mylan N.V.

Novartis International Ag

Eli Lily and Company

Merck & Co., Inc.

Glaxosmithkline Plc (Gsk)

Purdue Pharma L.P.

Endo Health Solutions, Inc. (Endo International Plc.)

Johnson & Johnson

Abbott Laboratories

Market Segmentations:

Pain Management Market, By Mode of Pain Management (2024–2032)

Drugs

Opioids

NSAIDs

Anesthetics

Anticonvulsants

Anti-depressants

Other Non-narcotic Analgesics

Devices

Neurostimulation Devices

Infusion Pumps

Ablation Devices

Pain Management Market, By Application (2024–2032)

Cancer Pain

Neuropathic pain

Facial Pain & Migraine

Musculoskeletal Pain

Trauma

Others

In conclusion, the pain management market is poised for continued growth in the coming years, fueled by demographic trends, technological advancements, and evolving treatment paradigms. With an increasing focus on personalized medicine and holistic approaches to pain management, there is ample opportunity for stakeholders to capitalize on emerging trends and address unmet needs in this rapidly evolving landscape. However, challenges such as regulatory scrutiny, reimbursement issues, and the need for robust clinical evidence remain significant hurdles that must be navigated to ensure the sustainable growth of the market and the delivery of effective pain relief solutions to patients worldwide.

Buy This Research Report: https://datahorizzonresearch.com/checkout-page/pain-management-market-2398

Regional Analysis:

The North American market, with a special focus on the United States, stands out as the leading hub for pain management solutions, primarily propelled by a notable prevalence of chronic pain ailments alongside a robust healthcare infrastructure. Notably, the United States allocates a staggering sum exceeding $100 billion annually toward healthcare expenditures dedicated to pain management and mitigating opioid dependency. The region has notably experienced heightened scrutiny surrounding opioid-centric pain relief medications, precipitating more stringent regulatory measures and a notable pivot towards non-opioid alternatives. Furthermore, advancements in interventional pain management methodologies, such as spinal cord stimulation and radiofrequency ablation, have garnered substantial attention and adoption within this geographic area.

[writerblogs]

Global Pharmaceutical Drug Delivery Market Is Estimated To Witness High Growth Owing To Growing R&D Activities & Increasing Prevalence of Chronic Diseases

The global pharmaceutical drug delivery market is estimated to be valued at USD 1,764.1 billion in 2022 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

The pharmaceutical drug delivery market refers to the technology and approaches used to deliver drugs and medications to the patients in an effective and convenient manner. It plays a crucial role in enhancing the therapeutic outcomes of the drugs while minimizing side effects. The market offers various delivery systems such as oral tablets, injections, transdermal patches, inhalers, and implantable devices. These systems are designed to improve drug bioavailability, target specific sites, provide controlled release, and enhance patient compliance.

B) Market Dynamics:

The market is driven by two main factors: growing R&D activities in drug delivery technologies and an increasing prevalence of chronic diseases.

Growing R&D Activities: Pharmaceutical companies are investing heavily in research and development to develop advanced drug delivery technologies. These technologies aim to improve drug efficacy, reduce dosing frequency, and enhance patient convenience. For example, novel drug delivery systems like nanoparticles and liposomes enable targeted drug delivery to specific cells or tissues, reducing systemic toxicity and improving therapeutic outcomes.

Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, cancer, and respiratory diseases has created a high demand for effective drug delivery systems. These systems help in managing chronic conditions by providing sustained drug release, increasing patient compliance, and improving overall treatment outcomes.

C) Market Key Trends:

One key trend in the Pharmaceutical Drug Delivery Market  is the increasing adoption of self-injection and wearable drug delivery devices. These devices offer convenience to patients and eliminate the need for frequent visits to healthcare facilities for drug administration. For instance, wearable insulin pumps and autoinjectors allow patients with diabetes to self-administer insulin, improving their quality of life and treatment adherence.

D) SWOT Analysis:

Strengths:

1. Advanced drug delivery technologies.

2. Increasing investments in R&D.

Weaknesses:

1. High costs associated with advanced drug delivery systems.

2. Stringent regulatory requirements.

Opportunities:

1. Growing demand for targeted drug delivery systems.

2. Expansion of the market in emerging economies.

Threats:

1. Intense competition among key players.

2. Potential side effects and safety concerns associated with new drug delivery methods.

E) Key Takeaways:

Paragraph 1: The global pharmaceutical drug delivery market is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period. This growth can be attributed to increasing R&D activities in drug delivery technologies and the rising prevalence of chronic diseases.

Paragraph 2: In terms of regional analysis, North America is expected to dominate the market due to well-established healthcare infrastructure, high healthcare expenditure, and a large patient pool. However, the Asia Pacific region is expected to witness the fastest growth due to increasing investments in healthcare, rising disposable income, and a growing aging population.

Paragraph 3: Key players operating in the global pharmaceutical drug delivery market include Johnson and Johnson, Merck & Co., Inc., Bayer AG, Pfizer, Inc., Novartis AG, Sanofi, Antares Pharma, Inc., Accord Healthcare, Inc., Abbott, and GSK. These companies are focusing on strategic collaborations, product launches, and acquisitions to strengthen their market presence and gain a competitive edge.

In conclusion, the global pharmaceutical drug delivery market is poised for significant growth driven by increasing R&D activities, advancements in drug delivery technologies, and the rising prevalence of chronic diseases. The market offers immense opportunities for key players to innovate and meet the growing demand for efficient and patient-friendly drug delivery systems.

[poonamcmi]

Global Pharmaceutical Drug Delivery Market Is Estimated To Witness High Growth Owing To Increasing

The global pharmaceutical drug delivery market is estimated to be valued at USD 1,764.1 billion in 2022 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

The pharmaceutical drug delivery market refers to the technologies and devices used to administer drugs to patients in a safe and effective manner. This includes various delivery systems such as oral, injectable, topical, transdermal, and inhalation among others. With the increasing prevalence of chronic diseases and the growing demand for targeted drug delivery, the market is witnessing significant growth. The advancement in drug delivery systems has enabled controlled and sustained release of drugs, enhancing patient compliance and therapeutic outcomes.

Market Dynamics:

The market is driven by two key factors, namely the increasing prevalence of chronic diseases and the growing need for efficient drug delivery systems. The rising incidence of chronic diseases such as cardiovascular disorders, cancer, diabetes, and respiratory diseases has led to an increased demand for effective drug delivery methods. Additionally, the need for targeted delivery systems that can deliver drugs to specific sites in the body has also fueled market growth.

For example, the development of nanotechnology-based Pharmaceutical Drug Delivery Market has allowed for targeted drug delivery to cancer cells, minimizing side effects and improving the overall efficacy of treatments. Similarly, the advent of biologics and gene therapies has created a demand for specialized delivery systems that can ensure the safe and effective delivery of these complex therapies.

Segment Analysis:

The market can be segmented based on the type of drug delivery system, route of administration, and region. Among these segments, the injectable drug delivery system dominates the market due to its widespread use and ability to deliver drugs directly into the bloodstream, offering rapid and efficient action. Within the injectable segment, prefilled syringes and autoinjectors are witnessing significant growth due to the convenience and ease of use they offer to both healthcare professionals and patients.

PEST Analysis:

Political: The pharmaceutical drug delivery market is influenced by government regulations and policies regarding drug approvals and pricing.

Economic: The market is driven by increasing healthcare expenditure and the growing demand for advanced drug delivery systems in both developed and developing countries.

Social: The increasing prevalence of chronic diseases and an aging population is driving the demand for efficient drug delivery systems.

Technological: The market is witnessing rapid technological advancements in drug delivery systems, such as the use of nanotechnology, biomaterials, and 3D printing.

Key Takeaways:

The global pharmaceutical drug delivery market is expected to witness high growth, exhibiting a CAGR of 4.4% over the forecast period, due to increasing demand for efficient and targeted drug delivery systems.

North America is expected to dominate the market, driven by the presence of key pharmaceutical companies and advanced healthcare infrastructure.

Key players operating in the global pharmaceutical drug delivery market include Johnson and Johnson, Merck & Co., Inc., Bayer AG, Pfizer, Inc., Novartis AG, Sanofi, Antares Pharma, Inc., Accord Healthcare, Inc., Abbott, and GSK.

The pharmaceutical drug delivery market is experiencing significant growth due to the increasing need for efficient drug delivery systems. With advancements in technology and a rising demand for targeted therapies, the market is expected to witness continued growth in the coming years.

[vanshika393]

Novel Drug Delivery Systems (NDDS) Market Size, Industry Share, Growth Demand, Supply Chain, Trends Future Outlook, Forecast 2030

The latest market report published by Credence Research, Inc. “Global Novel Drug Delivery Systems (NDDS) Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2030. The global demand for novel drug delivery systems was valued at USD 12.1 Billion in 2022 and is expected to reach USD 49.0 Billion in 2030, growing at a CAGR of 22.10% between 2023 and 2030.

Novel Drug Delivery Systems (NDDS) refer to innovative approaches and techniques used to deliver pharmaceutical compounds to the body in a controlled and targeted manner. The goal of NDDS is to optimize the therapeutic efficacy, safety, and patient compliance of drugs while minimizing side effects and reducing the frequency of administration. This field has gained immense importance in the pharmaceutical industry due to its potential to revolutionize drug therapies and improve patient outcomes.

Traditional methods of drug delivery, such as oral tablets or injections, often suffer from limitations like variable absorption, rapid metabolism, and limited bioavailability. NDDS addresses these challenges by designing novel ways to control the release, distribution, and targeting of drugs within the body. This enables a more personalized and efficient approach to drug administration.

Major Players Analysis in Novel Drug Delivery Systems (NDDS) Market:

One such player is Johnson & Johnson, a global healthcare company known for its wide range of medical devices and pharmaceuticals. They have invested heavily in developing advanced drug delivery systems that improve patient outcomes and enhance therapeutic efficacy.

Another key player is Pfizer Inc., one of the world's largest pharmaceutical companies. With their expertise in drug formulation and delivery technologies, they have developed novel solutions that address specific challenges in delivering drugs to target sites effectively.

Novartis AG is also a prominent player in this space, focusing on developing innovative drug delivery platforms that enable precise targeting and controlled release of therapeutics. Their commitment to improving patient compliance has led to the development of user-friendly delivery systems.

Opportunities in Novel Drug Delivery Systems (NDDS) Market

One major opportunity lies in the development of innovative drug delivery technologies. Researchers and pharmaceutical companies are exploring novel approaches such as nanotechnology, microparticles, and liposomes to enhance drug efficacy and minimize side effects. These advancements allow for precise drug targeting to specific areas within the body, improving treatment outcomes.

Another opportunity arises from the growing need for personalized medicine. NDDS offers tailored solutions that can be customized based on individual patient characteristics and requirements. This approach not only improves patient compliance but also enhances therapeutic outcomes by delivering drugs at optimal dosages and times.

Furthermore, there is immense potential in expanding NDDS applications beyond traditional pharmaceuticals. The integration of biologics, gene therapies, and regenerative medicine with advanced drug delivery systems opens up new avenues for innovation in disease management.

Browse 240 pages report Novel Drug Delivery Systems (NDDS) Market By Route of administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery System) By Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems) - Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/novel-drug-delivery-systems-ndds-market

Risks in the Novel Drug Delivery Systems (NDDS) Market:

Regulatory Challenges: Developing and commercializing NDDS technologies can be hindered by complex and evolving regulatory requirements. Ensuring compliance with safety and efficacy standards can be time-consuming and costly.

Clinical Trials and Validation: Demonstrating the safety and effectiveness of NDDS in clinical trials can be challenging. The unique characteristics of these systems may require specialized study designs and endpoints, which could delay the development process.

Technical Hurdles: Designing and manufacturing NDDS technologies with consistent quality and performance can be technically demanding. Ensuring reproducibility and scalability can pose significant challenges.

Growth Factor Worldwide in Novel Drug Delivery Systems (NDDS) Market

The Novel Drug Delivery Systems (NDDS) market is experiencing tremendous growth worldwide, driven by several key factors. One of the major drivers is the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. As the demand for more effective treatments rises, pharmaceutical companies are investing heavily in research and development to develop novel drug delivery systems that can deliver drugs directly to target sites in a controlled manner.

Another growth factor is the advancements in technology. From nanotechnology-based delivery systems to implantable devices and smart drug carriers, there has been a significant leap forward in NDDS technologies. These innovations not only enhance drug efficacy but also improve patient compliance by reducing side effects and optimizing therapeutic outcomes.

Moreover, the growing geriatric population globally has contributed to the expansion of the NDDS market. Elderly individuals often face challenges with traditional oral medications or injections due to issues like difficulty swallowing or poor adherence. Novel drug delivery systems offer alternative routes such as transdermal patches or inhalers that are easier for older adults to use.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Novel Drug Delivery Systems (NDDS) Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Novel Drug Delivery Systems (NDDS) Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/novel-drug-delivery-systems-ndds-market

Visit:  https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/synthetic-bone-graft-substitutes-market

Browse Our Blog: https://www.linkedin.com/pulse/novel-drug-delivery-systems-ndds-market-size-worth-usd-shukla/?published=t

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[efrost]

Pharmaceutical Drug Delivery Market Unidentified Segments – The Biggest Opportunity Of 2023

The Latest Released market study on Global Pharmaceutical Drug Delivery market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Pharmaceutical Drug Delivery market. What’s keeping Johnson & Johnson (United States)

Novartis International (Switzerland)

Merck Group (Germany)

Roche Holding AG (Switzerland)

Pfizer Inc. (United States)

Bayer AG (Germany)

Becton, Dickinson and Company (United States)

GlaxoSmithKline (United Kingdom)

3M (United States)

Sanofi (France)

Genmab (Denmark)

Boehringer Ingelheim (Germany)

AstraZeneca (United Kingdom)

Takeda (Japan)

Amgen (United States)

Bristol-Myers Squibb (United States)

Gerresheimer AG (Germany)

OthersKeep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Pharmaceutical Drug Delivery market recently published by AMA A pharmaceutical drug delivery system (DDS) is a formulation or a device used to deliver a therapeutic substance into the body. This system works by delivering medications to specific parts of the body via a medium that can control therapy administration via a physiological or chemical trigger. DDS is used to improve the efficacy and safety of a drug by regulating the rate, time, and location of drug release in the body. Additionally, different routes of administration are used to introduce drug delivery systems into the body, such as oral drug delivery, pulmonary drug delivery, injectable drug delivery, nasal drug delivery, and others.

The Pharmaceutical Drug Delivery Market segments and Market Data Break Down by Type (Nano- and Micro-Particles, Transdermal Patches, Drug Reservoir Implants, Antibody-Drug Conjugates, Others), Application (Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases, Others), Route of Administration (Buccal, Nasal, Oral, Transdermal, Others), End-User (Hospitals, Ambulatory Surgery Centre, Diagnostic Centre, Other)

On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa. What’s Trending in Market : Increased demand for the various medicines like vitamin C, antivirals, during the COVID-19 pandemic spiked the demand for the pharmaceutical drug delivery

Market Challenges: Rise in Number of Drug Recalls and Drug Failures Restricts the Growth of Pharmaceutical Drug Delivery Market

Increasing Cost of Healthcare Expenditure

Market Opportunities: Rising Investments in the Bio-Pharmaceutical Industry towards the Development of New Life-Saving Drugs

Highlights of Influencing Drivers: Growing Prevalence of Chronic Diseases such as Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, and Neurological disorders

Surging Geriatric Population across the Globe Presented By

AMA Research & Media LLP

[rohit890]

Cold Pain Therapy Market Key Players, Share, Trends, Sales, Segmentation And Forecast To 2031

Market Overview

The global cold pain therapy market was valued at USD 1.8 billion in 2021 and it is anticipated to grow at 5.9% CAGR during the projection period to reach up to USD 3.2 billion by 2031.

Cold pain therapy includes the usage of cold materials to relieve pain. Cryotherapy is generally used as an essential injury management skill. Ice packs are applied to inflammations and injuries to help reduce pain and swelling. Studies suggest that cold compression slows blood flow to the injury, thereby reducing pain, inflammation, and muscle spasm. Ice packs are effective, inexpensive, and drugless methods to relieve pain from sprains, strains, bruises, tendinitis, and swelling caused due to trauma to superficial tissues. Cold packs, used on inflammations act as a primary analgesic to relieve pain. Cold pain therapy is primarily used on fresh injuries such as ligament sprains, muscle sprains, and severe bruises. This therapy is used for chronic overuse or tissue fatigue injuries such as carpal tunnel syndrome, tennis elbow, supraspinatus tendinitis, iliotibial band syndrome, patellofemoral pain syndrome, and plantar fasciitis.

View Detailed Report Description: https://www.globalinsightservices.com/reports/cold-pain-therapy-market/

Market Dynamics

The key factor boosting the market growth is increasing the number of hip and knee surgeries. There has been observed that aging-related changes in the musculoskeletal system increase the propensity to osteoarthritis (OA), and the severity of the disease is closely related to other OA risk factors such as joint injury, obesity, genetics, and anatomical factors that affect joint mechanics. OA is not an inevitable consequence of growing old, although older age is the greatest risk factor for OA. The market demand for surgical treatment, including joint replacement surgery (hip and knee replacement), is expected to increase significantly, owing to the rapidly increasing aging population across the globe.

Similarly, the increasing adoption of analgesic patches is also refueling the market growth. Analgesic patches feature a transdermal drug delivery system, which is a non-invasive mode of medication delivery through the skin. Patches deliver an analgesic drug at a fixed rate across the dermis, while placed on the skin. The use of analgesic patches through transdermal drug delivery systems offers certain advantages over oral medications.

Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10258

The key players in the global cold pain therapy market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1–833–761–1700

[rootsanalysis-blog]

DRIVEN BY THE INCREASED ADOPTION AND RISING UNMET NEED ASSOCIATED WITH PARENTERAL DRUGS, INDUSTRY STAKEHOLDERS HAVE MADE SIGNIFICANT INVESTMENTS TOWARDS THE DEVELOPMENT OF ORALLY ADMINISTERED PROTEIN AND PEPTIDE THERAPEUTICS

Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics.

 Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions   has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides. 

 To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/192/request-sample.html

  Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future.

  For additional details, please visit https://www.rootsanalysis.com/reports/view_document/oral-proteins-and-peptides-market/192.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.       Targeted protein degradation market, 2022-2035

2.       Cell Therapy Manufacturing Market, 2021-2030

3.       Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[marketresearchlatestreports]

Advanced Drug Delivery Market Future Outlook: Analyst View

The advanced drug delivery market is expected to expand at a CAGR of 16.0%, reaching the estimated value of USD 1,95,132.45mn between 2020 to 2030.

Researchmoz elucidates the market dynamics of the advanced drug delivery market including market size, growth drivers, restraints, trends, opportunities, segment dominance, and competitive edge.

The burgeoning chronic diseases are expected to strengthen the market during the forecast period.

Factors Driving and Restraining the Market

Some of the determinants of the growth of the advanced drug delivery market include-

The advanced technology in the drug delivery system is expected to drive the market towards significant growth.

For instance- West Pharmaceuticals getting into an agreement with Corning Incorporated for advanced technology for an advanced injectable drug delivery system to offer better safety for patients

Benefits such as target-oriented therapy, reduced dosing frequency, lower toxicity, and increased efficacy are anticipated to bolster the market significantly during the forecast period.

Rising investment in research and development in biotechnology and genetic engineering is expected to boost the demand for advanced drug delivery in the forthcoming years.

The controlled dosing system provides better patient compliance, and easy treatment methods, owing to the market expansion of advanced drug delivery during the forecast period.

The rapid development in nanotechnology and the development of nanoparticles to overcome the barriers of conventional methods of drug delivery are expected to drive the expansion of the market in the following years.

Analyst’s View

The global advanced drug delivery market is expected to grow exponentially at a noteworthy CAGR of 16.0% between 2020 to 20230, marking up to the estimated value of USD 1,95,132.45mn.

The first drug delivery system originated in 1855, in the form of syringes, however, it is since 1970 that the advent of the drug delivery system started gaining traction, now paving way for advanced drug delivery systems with next-generation drug delivery technologies.

The development of nanoparticles aims at the controlled release of drugs offering therapeutic efficacy and lower toxicity to meet the unmet needs in healthcare facilities.

Some of the existing key players of the advanced drug delivery market are –

Alnylam Pharmaceuticals Inc.

Endo International Plc.

Biogen Limited

Micropoint Technologies

Bausch Health Companies Inc. (Bausch & Lomb)

Altaris Capital Partners Llc. (Kindeva Drug Delivery)

Novo Nordisk A/S

Takeda Pharmaceutical Company Limited.

Johnson & Johnson (Johnson & Johnson Vision)

Ocular Therapeutix Inc.

Read More:

https://www.beetribune.com/advanced-drug-delivery-market-key-insights/

Product/Type Disposition (Revenue in USD million)

Oral Drug Delivery System

Injection based Drug Delivery System

Inhalation/ Pulmonary Drug Delivery System

Transdermal Drug Delivery System

Parenteral Drug Delivery System

Application Disposition (Revenue in USD million)

Liposomes

Nano Particles

Microspheres

Monoclonal Antibodies

Others

End Users Dispositions (Revenue in USD million)

Hospitals

Specialized Clinics

Clinical Research & Development Centres

Regional Disposition

U.S.

Canada

UK.

Germany

France

China

India

Japan

South Korea

Brazil

Mexico

Key Takeaways

The development of smart drug delivery is quintessential for intelligently targeted therapeutics.

Groundbreaking approaches and strategies such as nanotechnology is expected to advance the treatment approaches and drug performances.

The controlled oral delivery system is expected to gain traction in the advanced drug delivery market due to being less expensive, easy to administer, and less painful as compared to other modes of drug delivery.

The market is moderately competitive; however, it is quite challenging to penetrate the market unless there is intensive research not just about the drugs but also about the possibilities of drug recalls and failures and their impacts.

Download Report PDF:

Advanced Drug Delivery Market

[andy1199posts]

Leading Players Operating in the Global Transdermal Drug Delivery System Market

Leading Players Operating in the Global Transdermal Drug Delivery System Market

Global Leading Players: Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Abbvie (US), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US) are the major players operating in the global transdermal drug delivery system market. Different Growth Strategies Adopted by Them: These…

[technolgy0411]

Transdermal Drug Delivery System Market Outlook: World Approaching Demand & Growth Prospect 2019-2027

The transdermal drug delivery system market was valued at US$ 6,063.85 million in 2019 and is projected to reach US$ 8,415.04 million 2027; it is expected to grow at a CAGR of 4.3% from 2020 to 2027.The sinus dilation market size is estimated to reach US$ 3,859.75 million by 2027 from US$ 1,918.73 million in 2019; it is expected to grow at a CAGR of 9.3% during 2019–2027.

Transdermal Drug Delivery System (TDDS) is described as a self-contained or discrete dosage form known as patches or semisolid forms that are applied to the intact skin. There are different types of semisolid forms, such as, creams, ointments, gels, and sprays. Dosage forms are designed to deliver a therapeutically effective amount of drug across a patient’s skin. The transdermal drug delivery system market is expected to witness a huge growth due to increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.

Novartis Ag, Johnson & Johnson Services, Inc., Glaxosmithkline Plc., Bayer Ag, Mylan N.V., Boehringer Ingelheim International Gmbh, Hisamitsu Pharmaceutical Co.,Inc., Luye Pharma Group, Purdue Pharma L.P., and Lavipharm are among the leading companies operating in the transdermal drug delivery system market.

Global Transdermal Drug Delivery System Market, By Regions, 2019 (%)

The report segments global transdermal drug delivery system market as follows:

By Type

Transdermal Patches

Matrix Patches

Microneedle Patches

Drug-In-Adhesive Patches

Reservoir Membrane Patches

Transdermal Semisolids

Sprays

Gels

Ointments

By Application

Cardiovascular Diseases

Central Nervous System Disorders

Pain Management

Hormonal Applications

Transdermal Estrogen Therapy

Testosterone Replacement Therapy

Other Applications

By End User

Hospitals and Clinics

Home Care Settings

Other End Users

By Geography

North America

US

Canada

Mexico

Europe

France

Germany

U.K

Spain

Italy

Asia Pacific (APAC)

China

India

Japan

Australia

South Korea

Middle East & Africa (MEA)

Saudi Arabia

U.A.E

South Africa

South & Central America (SCAM)

Brazil

Argentina

Contact Us

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email Id: sales@theinsightpartners.com

[omkarpatel]

Pain Patch Market is Estimated to Witness High Growth Owing to Increased Demand for Alternative Pain Treatment Options

A pain patch, also known as transdermal analgesic patch, is a medicated adhesive patch that is placed on the skin to deliver a particular dose of medication through the skin and into the bloodstream. Pain patches provide several advantages over traditional pain medication methods such as pills and injections as they offer precisely metered doses of pain relief and prevent unpleasant side effects like nausea, vomiting, and constipation. With growing awareness about alternative pain treatment options and rising cases of arthritis and lower back pain, the demand for pain patches is surging. The global Pain Patch market is estimated to be valued at US$ 5.29 Bn in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: Increased demand for alternative pain treatments without side effects is a major opportunity driving the growth of the Pain Patch market. People are increasingly looking for pain relief options that offer targeted treatment and do not cause systemic side effects. Pain patches have emerged as an effective alternative as they deliver medication directly into the bloodstream around the application site, thus offering localized pain relief. They are also convenient to apply and discreet to wear under clothes. With continued awareness about such patient-centric treatment options, the demand for pain patches is expected to increase significantly over the forecast period. Porter's Analysis Threat of new entrants: The pain patch market is moderately difficult to enter due to the requirement of extensive R&D, expertise in dermatological formulations, and patent protections of existing products. Bargaining power of buyers: Individual consumers have moderate bargaining power due to the availability of generic versions and branded alternatives for treating pain. However, large pharmaceutical companies and pharmacy chains have high bargaining power to negotiate prices. Bargaining power of suppliers: The bargaining power of raw material suppliers is moderate due to the availability of substitutes and less differentiation in materials. Threat of new substitutes: The threat is moderate to high as alternative delivery forms and new drug entities continue to emerge for pain management. SWOT Analysis Strengths: Non-invasive nature of patches provides convenience. Strong R&D capabilities of major players. Weaknesses: Lower absorption rates than other delivery forms. Requirement of frequent application and replacement. Opportunities: Untapped markets in developing regions. New technologies to improve drug penetration. Threats: Patent expiries of blockbuster brands. Price erosion due to generics. Key Takeaways The global pain patch market is expected to witness high growth during the forecast period due to the increasing prevalence of chronic pain disorders, growing geriatric population, and technological advancements. The global Pain Patch Market is estimated to be valued at US$ 5.29 Bn in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023-2030. North America currently dominates the market driven by the rising healthcare spending and availability of reimbursements.

Key players operating in the pain patch market are Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Mylan N.V., Endo Pharmaceuticals, Teikoku Pharma USA, Inc., Acorda Therapeutics, Ibsa Institut Biochimique SA, Alembic Pharmaceuticals, Noven Pharmaceuticals, Inc., Teva Pharmaceuticals, Strativa Pharmaceuticals, Galen Limited, and Napp Pharmaceuticals. Hisamitsu Pharmaceutical Co., Inc. dominates with its popular brand Minitran for transdermal administration of fentanyl for pain management.

[ken-research-market-research]

Upcoming Trends Of The Silicone Sealant Globally Market Outlook: Ken Research Buy Now The silicone sealant is a gelatinous material majorly dependent on the silicone polymers that can be utilized in several industries to chunk the passage of the fluids by sealing and bonding.

[wiseguy2218]

Global Controlled Release Drug Delivery Market